Migrating potential patient safety risk: Omeprazole 40mg and Flecainide 100mg capsules

Submission to Pharmaceutical Society of New Zealand, 20 March 2025

Also in this category

Submissions

Draft guidance on establishing and sustaining human milk banks

Submission to Allen & Clarke

View resource
Submissions

Proposal to enter into a new supply agreement for the COVID-19 vaccine

Submission to Pharmac

View resource
Submissions

Proposal to support access to budesonide with eformoterol inhalers

View resource